Company Description
VivoSim Labs, Inc., a pharmaceutical and biotechnology services.
Its segments include research and development R&D and Mosaic Cell Sciences. The company focuses on providing testing of drugs and drug candidates in three-dimensional 3D human tissue models of liver and intestine.
Its liver testing servies such as silico liver toxicology prediction, and drug candidate screening. In addition, the company focuses on developing FXR314 in inflammatory bowel disease IBD, including ulcerative colitis UC based on demonstration of clinical promise in 3D human tissues, as well as preclinical data.
The Mosaic Cell Sciences division to serve as a key source of certain primary human cells it utilizes in its research and development efforts; and 3D human tissue platform is multifaceted.
The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025.
The company was incorporated in 2007 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
Contact Details
Address: 11555 Sorrento Valley Road San Diego, California 92121 United States | |
| Phone | 858 224 1000 |
| Website | vivosim.ai |
Stock Details
| Ticker Symbol | VIVS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001497253 |
| ISIN Number | US68620A3023 |
Key Executives
| Name | Position |
|---|---|
| Keith E. Murphy | Executive Chairman and Corporate Secretary |
| Norman Staskey | President, Chief Financial Officer and Principal Financial Officer |
| Dr. Curtis M. Tyree Ph.D. | Senior Vice President of Strategy and Business Development |